AZN · AstraZeneca
AI read · Good for AZN
The AI's read
A positive recommendation moves Baxfendy closer to reaching patients in Europe. The U.S. approval already gives it one approved market, and AstraZeneca has said peak annual sales could exceed $5 billion. The European Commission still has to make the final decision, so those sales remain a possibility. Even so, the recommendation strengthens the drug's growth prospects.